Core Insights - Organon reported $1.59 billion in revenue for Q2 2025, reflecting a year-over-year decline of 0.8% and an EPS of $1.00, down from $1.12 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $1.55 billion by 2.63%, while the EPS surpassed the consensus estimate of $0.94 by 6.38% [1] Revenue Performance by Segment - Established Brands in the U.S. for Respiratory (Singulair) generated $2 million, slightly above the $1.95 million estimate, with no year-over-year change [4] - Women's Health International for Nexplanon/Implanon NXT achieved $77 million, exceeding the $75.7 million estimate, marking a 10% increase year-over-year [4] - Women's Health U.S. for NuvaRing reported $7 million, matching estimates but showing a 30% decline year-over-year [4] - Women's Health International for Follistim AQ reached $43 million, surpassing the $41.53 million estimate, reflecting a 7.5% increase year-over-year [4] - Women's Health for Nexplanon/Implanon NXT totaled $240 million, below the $258.98 million estimate, with a slight decline of 0.8% year-over-year [4] - Women's Health for Follistim AQ generated $74 million, exceeding the $69.57 million estimate, showing a 19.4% increase year-over-year [4] - Total revenue for Established Brands was $936 million, above the $905.64 million estimate, but down 2.8% year-over-year [4] - Biosimilars total revenue reached $173 million, exceeding the $153.98 million estimate, with a year-over-year increase of 5.5% [4] - Total revenue for Women's Health was $462 million, slightly below the $471.79 million estimate, with a year-over-year increase of 2.9% [4] - Other revenue totaled $23 million, above the $21.74 million estimate, but down 25.8% year-over-year [4] - Women's Health for NuvaRing reported $28 million, exceeding the $22.99 million estimate, with a 3.5% decline year-over-year [4] - Biosimilars for Renflexis generated $63 million, surpassing the $56.8 million estimate, but reflecting an 8.7% decline year-over-year [4] Stock Performance - Organon's shares returned -0.5% over the past month, compared to a +1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - Analysts project Organon (OGN) will report quarterly earnings of $0.94 per share, a decline of 16.1% year over year, with revenues expected to reach $1.55 billion, down 3.4% from the same quarter last year [1] Revenue Projections - Revenue from Women's Health for Nexplanon/Implanon NXT is estimated at $258.98 million, reflecting a year-over-year increase of +7% [4] - Revenue from Women's Health for Follistim AQ is projected to be $69.57 million, indicating a year-over-year increase of +12.2% [4] - Total revenue from Established Brands is expected to be $905.64 million, showing a decline of -6% from the prior-year quarter [4] - Revenue from Biosimilars Total is anticipated to be $153.98 million, representing a decrease of -6.1% from the year-ago quarter [5] - Revenue from Women's Health in the U.S. for Nexplanon/Implanon NXT is estimated at $183.28 million, indicating a year-over-year increase of +7.2% [5] - Geographic Revenue from the U.S. is projected to be $437.92 million, reflecting a year-over-year increase of +12.9% [5] - Revenue from Women's Health in the U.S. for NuvaRing is expected to be $7.00 million, suggesting a decline of -30% year over year [6] - Revenue from Women's Health in the U.S. for Follistim AQ is projected to reach $28.03 million, indicating a year-over-year increase of +27.4% [6] - Revenue from Established Brands in the U.S. for Respiratory- Other is expected to be $8.30 million, reflecting a year-over-year increase of +3.8% [7] - Geographic Revenue from Other International is projected to be $21.74 million, indicating a decline of -37.9% year over year [7] - Revenue from Established Brands International for Non-Opioid Pain, Bone and Dermatology- Other is expected to reach $72.24 million, suggesting a decline of -1% year over year [7] - Revenue from Established Brands International for Non-Opioid Pain, Bone and Dermatology- Diprospan is projected to be $37.63 million, reflecting a year-over-year increase of +1.7% [8] Stock Performance - Over the past month, Organon shares have returned -2.6%, contrasting with the Zacks S&P 500 composite's +2.3% change [8] - Organon currently holds a Zacks Rank 2 (Buy), indicating potential outperformance against the overall market in the near future [8]

Core Insights - Organon reported $1.51 billion in revenue for Q1 2025, a year-over-year decline of 6.7% and an EPS of $1.02 compared to $1.22 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $1.52 billion, resulting in a surprise of -0.73%, while the EPS exceeded expectations by 14.61% [1] Revenue Breakdown - Revenue from Established Brands-International-Respiratory-Dulera was $10 million, below the estimated $12.32 million, reflecting a -23.1% change year-over-year [4] - Revenue from Established Brands-International-Respiratory-Clarinex was $34 million, slightly below the estimate of $34.23 million, showing a -5.6% change year-over-year [4] - Revenue from Women's Health-International-NuvaRing was $16 million, below the estimated $17.23 million, representing a -27.3% change year-over-year [4] - Revenue from Women's Health-U.S.-NuvaRing was $6 million, compared to the estimated $8.12 million, indicating a -62.5% year-over-year change [4] - Revenue from Women's Health-Nexplanon/Implanon NXT was $248 million, exceeding the estimate of $234.36 million, with a +12.7% change year-over-year [4] - Revenue from Women's Health-Follistim AQ was $69 million, surpassing the estimate of $55.63 million, reflecting a +50% change year-over-year [4] - Total revenue from Established Brands was $887 million, below the estimated $918.89 million, showing an -11.4% change year-over-year [4] - Total revenue from Biosimilars was $141 million, slightly below the estimate of $144.88 million, representing a -17.1% change year-over-year [4] - Total revenue from Women's Health was $463 million, exceeding the estimate of $435.11 million, with a +9.7% change year-over-year [4] - Total revenue from Other was $22 million, below the estimated $25.18 million, indicating a -24.1% change year-over-year [4] - Revenue from Women's Health-NuvaRing was $22 million, below the estimated $24.64 million, reflecting a -42.1% change year-over-year [4] - Revenue from Biosimilars-Renflexis was $57 million, slightly above the estimate of $53.74 million, showing a -17.4% change year-over-year [4] Stock Performance - Shares of Organon have returned -12.2% over the past month, compared to the Zacks S&P 500 composite's -0.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Analysts expect Organon (OGN) to report quarterly earnings of $0.92 per share, reflecting a year-over-year decline of 24.6% and revenues of $1.54 billion, down 4.9% from the previous year [1] - There has been a downward revision of 1.7% in the consensus EPS estimate over the last 30 days, indicating a reconsideration of initial forecasts by analysts [1][2] Revenue Estimates - Revenue from Women's Health for Nexplanon/Implanon NXT is projected at $236.63 million, showing a year-over-year increase of 7.6% [4] - The consensus estimate for Biosimilars Total revenue is $153.47 million, indicating a decline of 9.7% from the year-ago quarter [4] - Revenue for Women's Health from NuvaRing is estimated at $25.26 million, reflecting a significant decrease of 33.5% year-over-year [4] - Revenue from Women's Health for Follistim AQ is expected to be $55.48 million, marking a year-over-year increase of 20.6% [5] - U.S. revenue for Nexplanon/Implanon NXT is projected at $165.06 million, indicating a growth of 7.9% from the previous year [5] - Geographic Revenue from the U.S. is expected to reach $407.08 million, suggesting a year-over-year increase of 9.7% [6] - Revenue from Women's Health for U.S. NuvaRing is forecasted at $8.12 million, indicating a substantial decline of 49.2% from the year-ago quarter [6] - Revenue from Women's Health for U.S. Follistim AQ is estimated at $18.97 million, reflecting a significant increase of 72.4% year-over-year [6] - Revenue from Established Brands in the U.S. for Respiratory- Other is projected at $7.68 million, indicating a year-over-year increase of 9.8% [7] - Geographic Revenue from Other International is expected to be $25.18 million, reflecting a decline of 13.2% from the prior-year quarter [7] - Revenue from Established Brands International for Non-Opioid Pain, Bone and Dermatology- Other is estimated at $68.21 million, suggesting a slight increase of 0.3% year-over-year [8] - Revenue from Established Brands International for Non-Opioid Pain, Bone and Dermatology- Diprospan is projected at $30.94 million, indicating a year-over-year increase of 6.7% [8] Stock Performance - Over the past month, Organon shares have declined by 15.9%, compared to a 4.3% decline in the Zacks S&P 500 composite [8]